Home » Posts tagged with » pemigatinib
Incyte bags Pemazyre FDA approval for cholangiocarcinoma treatment

Incyte bags Pemazyre FDA approval for cholangiocarcinoma treatment

Pemazyre FDA approval : US biopharma company Incyte has bagged accelerated approval from the US Food and Drug Administration (FDA) for Pemazyre (pemigatinib) for the treatment of cholangiocarcinoma, a rare type of cancer occurring in the bile ducts. The approval is for adult patients having certain types of previously treated, advanced cholangiocarcinoma. According to the […]

Incyte secures FDA priority review for pemigatinib in cholangiocarcinoma

Delaware-based pharma company Incyte has secured priority review for pemigatinib from the US Food and Drug Administration (FDA) for the treatment of locally advanced or metastatic cholangiocarcinoma. The priority review for pemigatinib is for the treatment of the condition in previously treated patients having FGFR2 fusions or rearrangements. Cholangiocarcinoma is a rare cancer that occurs […]

Continue reading …
Incyte, Innovent announce collaboration for three cancer drugs in China

US pharma company Incyte and Chinese biopharma company Innovent Biologics through their respective subsidiaries have entered into a deal worth up to $391.5 million for three investigational cancer drugs discovered and developed by the former. The three investigational cancer drugs – pemigatinib, a FGFR1/2/3 inhibitor, itacitinib, a JAK1 inhibitor and parsaclisib, a PI3Kδ inhibitor, are […]

Continue reading …